🇺🇸 FDA
Patent

US 9913841

6-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive airway diseases

granted A61KA61K31/353A61K31/355

Quick answer

US patent 9913841 (6-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive airway diseases) held by Sulfateq B.V. expires Mon Mar 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sulfateq B.V.
Grant date
Tue Mar 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K31/353, A61K31/355, A61K31/4025, A61K31/453